Allogenic Human Mesenchymal Stem Cells for Alzheimer’s Disease

• Researchers at Stemedica Cell Technologies are looking for 40 patients ages 50-88 to test the safety and efficacy of using stem cells as a treatment for mild to moderate dementia due to Alzheimer’s. The study will split 50/50 with half the patients being treated with a placebo twice over a 6-month period and the other group will receive 1.5 million human mesenchymal cells per kilogram of body weight intravenously on the same dates the other group receives placebo injections. Over the next 18 months, the patients will be monitored for any adverse effects as well as any improvement in their neurological functioning. Eligible patients must have diagnosed dementia at least 3 months prior to the beginning of treatment and must have never had prior stem cell treatment, prior cancer, or any prior intracranial hemorrhages. Please visit the clinical trials website for more information.
• https://clinicaltrials.gov/ct2/show/NCT02833792?term=Stem+cells&recrs=abde&cond=Dementia&cntry=US&draw=2&rank=1

Alzheimer’s Disease Stem Cells Multiple Infusions

• Researchers from the University of Miami are looking for 10 patients ages 50-85 to test the safety and efficacy of using stem cells as a treatment for dementia. This study will split patients into a high dose and a low dose group. The high dose group will receive intravenous infusions of 200 million human mesenchymal stem cells every 13 weeks for a year, totaling 800 million stem cells. The low dose group will receive intravenous infusions of 100 million human mesenchymal stem cells every 13 weeks for a year, totaling 400 million stem cells. Following treatment, the patients will be monitored for up to 65 weeks for adverse effects and will also be given multiple cognitive functioning tests and have their score compared to their baseline score prior to treatment. Eligible patients must have diagnosed dementia due only to Alzheimer’s, must have no abnormal screening laboratory values, must have no history of seizures, and must have any other neurodegenerative disease. Please visit the clinical trials website for more information.
• https://clinicaltrials.gov/ct2/show/NCT04040348?term=Stem+cells&recrs=abde&cond=Dementia&cntry=US&draw=2&rank=3

A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer’s Disease

• Researchers from the Nature Cell Co. are currently completing trials to test the safety and efficacy of using stem cells as a treatment for dementia. Patients will be randomly put into placebo or treatment groups and will receive an IV of either placebo or adipose tissue derived mesenchymal stem cells 9 times at 2-week intervals. The patients will then return at weeks 30 and 52 for follow-up appointments. At these appointments, the patients will be monitored for any adverse effects and will also be given multiple cognitive functioning tests and have their score compared to their baseline score prior to treatment. Eligible patients must have diagnosed dementia due only to Alzheimer’s, must have no abnormal screening laboratory values, must have no history of seizures, and must have any other neurodegenerative disease. Please visit the clinical trials website for more information.
• https://clinicaltrials.gov/ct2/show/NCT03117738?term=Stem+cells&recrs=abde&cond=Dementia&cntry=US&draw=5&rank=14